Efficacy of recombinant human soluble thrombomodulin in patients with sepsis and disseminated intravascular coagulation in the gastroenterology field
| Autor: | Nobuhito Taniki, Ryo Shimizu, Hiroya Ueyama, Ryo Kanazawa, Sumio Watanabe, Junko Kato, Tomoyasu Ito, Jinkan Sai, Hiroaki Saito, Taro Osada, Shuichiro Shiina, Akihito Nagahara |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2015 |
| Předmět: |
medicine.medical_specialty
Pathology Fibrinogen Gastroenterology General Biochemistry Genetics and Molecular Biology Fibrin law.invention Sepsis law Internal medicine hemic and lymphatic diseases medicine Platelet General Pharmacology Toxicology and Pharmaceutics Disseminated intravascular coagulation biology business.industry General Neuroscience General Medicine Articles medicine.disease Soluble thrombomodulin biology.protein Recombinant DNA business Gastroenterology (field) medicine.drug circulatory and respiratory physiology |
| Popis: | Recombinant human soluble thrombomodulin (rTM) was approved recently and has been used for treatment of disseminated intravascular coagulation (DIC). The aim of the present study was to evaluate the efficacy of rTM for DIC. The data of 53 inpatients with sepsis-induced DIC were retrospectively analyzed. Patients were classified into the rTM treatment group (n=25) and conventional treatment group (rTM not used) was the control group (n=28). Diagnosis of DIC was made according to the criteria for acute DIC of the Japan Association of Acute Medicine. Platelet count, prothrombin time-international normalized ratio, levels of fibrin/fibrinogen degradation products (FDP), C-reactive protein and DIC scores were measured on days 0, 3 and 7. Furthermore, the DIC resolution rate was assessed on days 3 and 7. Prior to treatment, DIC scores were 5.0±1.0 in the rTM group and 5.9±1.3 in the control group (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|